Immunology
Study links a distinct CD14+ monocyte state to fatigue and breathing symptoms in long COVID
Сообщено ИИ Изображение, созданное ИИ Проверено фактами
Researchers analyzing immune cells from people with long COVID have identified a distinct molecular state in CD14+ monocytes—labeled “LC-Mo”—that was more prevalent among patients whose initial COVID-19 illness was mild to moderate and that tracked with reported fatigue and respiratory symptoms, along with higher levels of inflammatory signaling molecules in blood plasma.
New research indicates that severe cases of COVID-19 or influenza can alter lung immune cells, potentially increasing cancer risk months or years afterward. The study, conducted by scientists at the University of Virginia, highlights the role of chronic inflammation in this process and emphasizes vaccination as a preventive measure. Findings suggest closer monitoring for affected patients to enable early detection.
Сообщено ИИ
Researchers at the University of Geneva have discovered that tumors can reprogram neutrophils, turning these immune cells from defenders against infection into promoters of cancer growth through the production of a molecule called CCL3. This finding, published in Cancer Cell, suggests CCL3 could serve as a marker for tracking tumor progression across various cancers. The study highlights how the tumor environment alters immune responses to favor disease advancement.
Trinity College Dublin researchers report that electrically stimulating human macrophages shifted them toward an anti‑inflammatory, tissue‑repairing state in laboratory tests, pointing to potential therapies for injuries and inflammatory disease. The peer‑reviewed findings appear in Cell Reports Physical Science.
Сообщено ИИ
A new study reveals that breastfeeding leads to a long-term surge in specialized immune cells in breast tissue, potentially reducing cancer risk. Researchers found these CD8+ T cells persist for decades, acting as guards against malignant cells. The findings suggest breastfeeding could enhance natural protection against aggressive breast cancers.
Researchers developed the first experimental mRNA-based therapy for ISG15 deficiency, a rare genetic mutation providing near-universal viral immunity, as reported on September 9, 2025.